Substituted indan derivatives
OwnerStefan Berg, Lennart Florvall +2inventors
InventorsStefan Berg, Lennart Florvall, Svante Ross, Seth-Olov Thorberg
Life of this patent
Estimating the term…
Loading patent…
OwnerStefan Berg, Lennart Florvall +2inventors
InventorsStefan Berg, Lennart Florvall, Svante Ross, Seth-Olov Thorberg
Estimating the term…
The present invention relates to new piperidyl- or piperazinyl-substituted indan derivatives having the formula I 1 wherein X is N or CH; Y is NR2CH2, CH2NR2, NR2CO, CONR2 or NR2SO2 wherein R2 is H or C1-C6 alkyl; R1 is H, C1-C6 alkyl or C3-C6 cycloalkyl; R3 is C1-C6 alkyl, C3-C6 cycloalkyl or (CH2)n-aryl, wherein aryl is phenyl or a heteroaromatic ring containing one or two heteroatoms selected from N, O and S and which may be mono- or di-substituted; n is 0-4; R9 is H, C1-C6 alkyl, C3-C6 cycloalkyl, OCF3, OCHF2, OCH2F, halogen, CN, CF3, OH, C1-C6 alkoxy, C1-C6 alkoxy-C1-C6 alkyl, NR6R7, SO3CH3, SO3CF3, SO2NR6R7, an unsubstituted or substituted heterocyclic or heteroaromatic ring containing one or two heteroatoms selected from N and O, wherein the substituent(s) is(are) C1-C6 alkyl; or COR8; wherein R6, R7 and R8 are as defined above, as (R)- enantiomers, (S)-enantiomers or racemates in the form of a free base or pharmaceutically acceptable salts or solvates thereof, a process for their preparation, pharmaceutical compositions containing said therapeutically active compounds and to the use of said active compounds in therapy.
A compound having the formula I
A compound which is 4-(4-methylpiperazin-1-yl)-N-(4-morpholinophenyl)indan-2-carboxamide in the form of a free base or a pharmaceutically acceptable salt or solvate thereof.
21 A compound as defined in claim 20 for use in the treatment of disorders in the central nervous system.
A compound as defined in claim 21 for use in the treatment of mood disorders, anxiety disorders, personality disorders, obesity, anorexia, bulimia, premenstrual syndrome, sexual disturbances, alcoholism, tobacco abuse, autism, attention deficit, hyperactivity disorder, migraine, memory disorders, pathological aggression, schizophrenia, endocrine disorders, stroke, dyskinesia, Parkinson's disease, thermoregulatory disorders, pain or hypertension.
33 A method according to claim 32 wherein the compound according to any one of claims 1-16 is used as a h5-HT1B antagonist.
A compound having the formula
Dependencies are inferred from the claim text.